New drug combo shows promise for hard-to-treat cervical cancer
NCT ID NCT04068753
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 26 times
Summary
This study tests a combination of two drugs, niraparib and dostarlimab, in 66 women with cervical cancer that has come back or gotten worse. The goal is to see if the combination is safe and can shrink tumors. Participants must have had prior treatment and provide a tumor sample for testing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT CERVIX CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Louisiana State University Health Science Center
New Orleans, Louisiana, 70112, United States
-
Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, 46202, United States
-
Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
-
University of Virginia Cancer Center
Charlottesville, Virginia, 22903, United States
Conditions
Explore the condition pages connected to this study.